Sanofi Pasteur, A Sanofi Company

This Phase 3 study tested two Sanofi COVID-19 vaccines (one targeting the original virus, another targeting two variants) in about 24,000 adults. The goal was to see if they could prevent COVID-19 safely. The trial was terminated early, so final results are limited, but the data …

This study tested an experimental RSV vaccine given to healthy infants at 6 and 12 months old alongside their regular vaccines. The goal was to see if the RSV vaccine still worked well when given at the same time. About 2,200 babies took part, but the study was stopped early.

This phase 3 study tested an intranasal RSV vaccine in about 6,300 healthy children aged 6 to 22 months. The goal was to see if two doses of the nasal spray could prevent lower respiratory tract infections caused by RSV. The trial was terminated early, so final results are not av…

This study tested a nasal spray RSV vaccine in nearly 1,000 healthy infants and toddlers aged 6 to 22 months. The goal was to see if a lower dose works as well as the standard dose and to check safety across different doses. The trial was ended early, so final results are not ava…

This early-stage study tested a new meningococcal B vaccine in 576 healthy people, from infants to adults. Researchers checked for side effects and measured immune responses, comparing the new vaccine to two already-approved ones. The goal was to see if the vaccine is safe and tr…

This study tested Sanofi's experimental mRNA vaccine against COVID-19 in 182 healthy adults aged 18 and older. The main goals were to check safety and measure the body's immune response. The trial was terminated early, so full results are not available.

This study tested whether a high-dose flu vaccine works better than the standard dose in preventing the flu in children aged 6 to 35 months. About 100 children took part, receiving either the high-dose or standard-dose shot. The study was stopped early, so results are limited.

This study compared a high-dose flu vaccine to the standard-dose shot in over 33,000 adults aged 65 and older. The goal was to see if the high-dose version could better prevent hospitalizations for heart and lung problems. The trial was terminated early, so the full picture is no…

This study compared a newer recombinant flu vaccine (RIV4, also called Supemtek or Flublok Quadrivalent) to the standard egg-based flu vaccine in 366 children aged 3 to 8 years. The goal was to see if the recombinant vaccine produced a similar immune response and was as safe. The…